Table of Contents
File the same invention with two patent offices and you can get two very different answers. A claim that sails through in Virginia can stall in Munich, and a single press release can quietly destroy your European rights before you ever apply. Understanding USPTO vs EPO patent requirements is what separates a clean dual filing from an expensive scramble. This guide walks through the nine differences that matter most in practice, with the statutes behind them and a filing strategy you can actually use.
USPTO vs EPO Patent Requirements: Why the Gaps Matter
Start with the common ground. Both offices are first-to-file, both grant a term of 20 years from the filing date, and both demand novelty, an inventive step, and a useful (industrially applicable) invention. The differences in USPTO vs EPO patent requirements live in how each office defines and tests those ideas.
The US system runs on Title 35 of the U.S. Code and the examiner’s manual (the MPEP). Europe runs on the European Patent Convention (EPC) and the EPO Guidelines. When the two diverge, they tend to diverge sharply, and a strategy tuned for one office can sink an application in the other.
- Same goal: a valid, enforceable patent that covers your commercial market.
- Different prior-art rules, subject-matter limits, claim economics, and post-grant attacks.
- One filing decision early (especially around public disclosure) often locks in or forfeits your options abroad.
Grace Period and Prior Art: The Costliest Trap
This is the difference that ends the most European cases before they start. In the US, 35 U.S.C. § 102(b)(1) gives inventors a one-year grace period: your own disclosure within twelve months before filing generally does not count as prior art against you.
Europe is unforgiving by comparison. Under Article 54 EPC, almost any disclosure available to the public before your filing date, including your own demo, paper, or sales pitch, becomes prior art that can defeat novelty. The narrow exceptions in Article 55 EPC cover evident abuse and certain official exhibitions, and they rarely save a careless founder.
The practical rule is simple: if Europe might matter, file before you disclose anything publicly. A provisional application or a PCT filing on file before the announcement preserves your priority date worldwide.
Patentable Subject Matter: Software, Business Methods, and AI
In the US, eligibility turns on 35 U.S.C. § 101 and the two-step framework from Alice Corp. v. CLS Bank. Abstract ideas, including many pure business methods, fail unless the claim adds an inventive concept that amounts to significantly more than the idea itself.
The EPO takes a different route. Article 52(2) and (3) EPC exclude programs for computers, business methods, mathematical methods, and presentations of information “as such.” A software invention is patentable only if it produces a further technical effect, solving a technical problem with technical means. The office then ignores non-technical features when judging inventive step.
- US: frame the invention as a concrete technical improvement to a computer or process, not an automated business idea.
- Europe: anchor every claim in a technical problem and a technical solution; commercial advantages alone do not count.
- AI inventions: both offices increasingly demand a clear technical purpose and enough disclosure to show the model actually works.
Claims, Unity of Invention, and Examination Style
Claim drafting habits do not transfer cleanly between offices. The EPO judges inventive step with its structured problem-solution approach, while US examiners apply the obviousness standard of 35 U.S.C. § 103 under the Graham and KSR framework. The same prior art can yield opposite conclusions.
Unity of invention is stricter in Europe. The EPO expects a single general inventive concept and will issue a non-unity objection (or extra search fees) when it sees more than one. US restriction practice under 35 U.S.C. § 121 is common too, but it usually routes the extra inventions into divisional applications rather than blocking the search.
Claim economics differ as well. The EPO charges claims fees once you exceed fifteen claims, and a much higher fee beyond fifty, which pushes European drafts toward lean claim sets. The USPTO charges excess fees once you pass twenty total or three independent claims. Europe also requires you to amend the description to match the allowed claims, a step that surprises many US practitioners and adds cost late in prosecution. Formalities differ too, right down to the figures, as our guide to EPO drawing requirements explains.
Costs, Translations, and the Unitary Patent
A US patent is a single national right with maintenance fees due at 3.5, 7.5, and 11.5 years after grant. A European patent has historically been a bundle: after grant you validate it country by country, often with translations and local agents, then pay separate annual renewal fees in each state.
The Unitary Patent, available since June 2023, changed the math. It lets you cover most participating EU countries with one post-grant right, one renewal payment, and litigation through the Unified Patent Court. It can lower cost and complexity if you want broad European coverage, but it also concentrates risk: one central revocation action can take down the whole unitary right.
Translation costs remain a real line item in Europe. The EPO examines in English, French, or German, and validation in non-Unitary states can still require translations. Budget for that early so the bill at grant is not a surprise.
Post-Grant Challenges: Opposition vs PTAB
How a competitor attacks your patent also differs. At the EPO, anyone can file a central opposition within nine months of grant under Article 99 EPC, a single proceeding that can revoke the patent across all designated states at once. It is fast, relatively cheap, and a favorite tool against weak European patents, as the European Patent Convention lays out.
In the US, challenges run through the Patent Trial and Appeal Board. Post-grant review must be filed within nine months of issuance, while inter partes review is generally available after that window on novelty and obviousness grounds based on patents and printed publications. The strategic takeaway: a single European opposition can be more dangerous, and cheaper for your opponent, than a US proceeding, so European claims need to be defensible on day one.
A Practical Filing Strategy for the US and Europe
Most companies do not choose between the offices; they sequence them. A common, sensible path looks like this:
- File first (provisional or PCT) before any public disclosure to protect both US and European novelty.
- Use the PCT route to keep your options open for up to 30 months while you learn which markets justify the spend.
- Draft with Europe in mind from the start: a clear technical problem, lean claims, and strong support for any feature you may need.
- Enter the EPO and the US national stage where the commercial case is real, not reflexively everywhere.
- Decide on the Unitary Patent at grant based on how many EU countries you actually need and your appetite for central revocation risk.
Get the disclosure timing and the first draft right, and the rest of the USPTO and EPO journey becomes a budgeting exercise rather than a rescue mission.
How PerspireIP Can Help
Filing in both the US and Europe rewards planning and punishes improvisation. PerspireIP drafts applications that hold up under both rulebooks, coordinates PCT and EPO strategy, and helps you spend where the market actually is. Talk to our team before your next disclosure or filing deadline.
Frequently Asked Questions
Is the grace period really gone at the EPO?
For practical purposes, yes. Europe has no general one-year grace period like the US. Any public disclosure before your filing date can be cited against you, so file before you present, sell, or publish.
Can one PCT application cover both the US and Europe?
A PCT application preserves your priority date and buys time, but it does not grant a patent. You still enter the US national stage and the EPO (or designated European states) separately to obtain enforceable rights.
Why did my US software patent get rejected at the EPO?
The EPO requires a further technical effect and ignores non-technical features when judging inventive step. A claim framed around a business or commercial advantage often fails in Europe even after allowance in the US.
What is the Unitary Patent and should I use it?
It is a single post-grant right covering most participating EU countries with one renewal fee and litigation in the Unified Patent Court. It can cut cost for broad coverage, but it exposes the whole right to a single central revocation action.
How long do US and European patents last?
Both last 20 years from the filing date, subject to paying maintenance or renewal fees. The US charges three maintenance fees after grant; Europe charges annual renewals, often per country.